Home ›
Data Desk › Rani Therapeutics Holdings Inc. gets a listing-standard notice from its exchange
MarginsX Data Desk · Exchange listing notices · Reverse split · Nasdaq deficiency notice · FDA approval
Rani Therapeutics Holdings Inc. gets a listing-standard notice from its exchange Rani Therapeutics Holdings Inc. (RANI) filed an 8-K on Nov 12, 2026 under Item 3.01, reporting a notice from its exchange about a listing standard it does not meet. (SEC EDGAR, 8-K, Nov 12, 2026)
By the MarginsX Data Desk, automated. Published November 14, 2026. Data as of November 12, 2026.
The stock
The Nasdaq screener puts its market value at $73.2M. (Nasdaq stock screener, Nov 13, 2026 )
Rani Therapeutics Holdings Inc. has about 1.9 months of cash at its recent burn
The 10-Q that Rani Therapeutics Holdings Inc. (RANI) filed on Nov 9, 2026 covers the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 9, 2026 )
Follow it up
The company's page on MarginsX, with its filings, health check and ownership. (capital.sophiaxt.com/stocks/RANI )
The filing on SEC EDGAR. (sec.gov )
The filing in the MarginsX reader, at the passage quoted. (MarginsX reader )
Automated from SEC filings and market data by the MarginsX Data Desk, written by template with no AI. For information only. Not investment advice.
Facts behind this article Fact Value Source As of Name Rani Therapeutics Holdings Inc. Source 2026-11-13 Who Rani Therapeutics Holdings Inc. (RANI) Source 2026-11-13 Symbol RANI Source 2026-11-13 Form 8-K Source 2026-11-12 Filed Nov 12, 2026 Source 2026-11-12 Item Item 3.01 Source 2026-11-12 Cap 73,244,876 USD Source 2026-11-13 Form 10-Q Source 2026-11-09 Filed Nov 9, 2026 Source 2026-11-09 Period end Sep 30, 2026 Source 2026-11-09
Sources
Automated from SEC filings and market data. No AI. For information only. Not investment advice.
Discuss in MarginsX More from the Data Desk
More on MarginsX Companies in this article Topics Related Data Desk stories Every Data Desk article: /desk · RSS